CSS
MCRB icon

Cubist Systematic Strategies’s Seres Therapeutics MCRB Stock Holding History

Cubist Systematic Strategies’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-4,283
Closed -$410K – 3704
2023
Q2 		$410K Buy
4,283
+3,795
+778% +$413K ﹤0.01% 2504
2023
Q1 		$55.4K Sell
488
-2,822
-85% -$305K ﹤0.01% 3551
2022
Q4 		$371K Buy
3,310
+3,301
+36,678% +$443K ﹤0.01% 3225
2022
Q3 		$1K Sell
9
-229
-96% -$23.5K ﹤0.01% 4366
2022
Q2 		$16K Sell
238
-1,944
-89% -$167K ﹤0.01% 4238
2022
Q1 		$311K Sell
2,182
-12,188
-85% -$1.87M ﹤0.01% 2822
2021
Q4 		$2.39M Sell
14,370
-1,540
-10% -$245K 0.02% 1214
2021
Q3 		$2.21M Buy
15,910
+14,525
+1,049% +$2.84M 0.03% 946
2021
Q2 		$660K Buy
+1,385
New +$584K 0.01% 1825
2021
Q1 		– Sell
-797
Closed -$391K – 2917
2020
Q4 		$391K Sell
797
-2,886
-78% -$1.69M 0.01% 1907
2020
Q3 		$2.09M Buy
3,683
+2,540
+222% +$845K 0.03% 876
2020
Q2 		$109K Buy
+1,143
New +$100K ﹤0.01% 2181
2017
Q4 		– Sell
-529
Closed -$170K – 2018
2017
Q3 		$170K Buy
+529
New +$145K 0.01% 1505

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Cubist Systematic Strategies's MCRB Position: Q3 2023 in Review

Cubist Systematic Strategies sold out of Seres Therapeutics (MCRB) in Q3 2023, closing a stake of 4,283 shares — an estimated $410K sold.

Cubist Systematic Strategies first reported a position in MCRB in Q3 2017 and held it in 13 quarters. The position peaked at $2.39M in Q4 2021. 134 funds tracked by Wall St. Rank hold MCRB as of Q3 2023.

  • Cubist Systematic Strategies reported no remaining Seres Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Cubist Systematic Strategies sold 4,283 Seres Therapeutics shares in Q3 2023, an estimated $410K.
  • Cubist Systematic Strategies first reported a position in Seres Therapeutics in Q3 2017 and held it in 13 quarters.
  • Cubist Systematic Strategies's Seres Therapeutics position peaked at $2.39M in Q4 2021.
  • 134 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2023.

Based on Cubist Systematic Strategies's 13F filing for Q3 2023, filed 14 Nov 2023.